The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have multiple myeloma (MM). This study will look at the effectiveness and safety in participants who take ixazomib in addition to lenalidomide and dexamethasone.
SparkCures ID | 925 |
---|---|
Trial Phase | Phase 4 |
Enrollment | 141 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
o Stem cell harvest and mobilization regimen is acceptable if clinically indicated, but must first be confirmed by the Takeda Medical Monitor.
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers